These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 28817997)

  • 21. Prevalence of disability improvement in relapsing-remitting multiple sclerosis patients treated with cladribine tablets.
    Signori A; Ponzano M; Alexandri N; Giovannoni G; Sormani MP
    Eur J Neurol; 2022 Jul; 29(7):2144-2147. PubMed ID: 35258154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
    Cook S; Vermersch P; Comi G; Giovannoni G; Rammohan K; Rieckmann P; Sørensen PS; Hamlett A; Miret M; Weiner J; Viglietta V; Musch B; Greenberg SJ;
    Mult Scler; 2011 May; 17(5):578-93. PubMed ID: 21228029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An update on cladribine for relapsing-remitting multiple sclerosis.
    Holmøy T; Torkildsen Ø; Myhr KM
    Expert Opin Pharmacother; 2017 Oct; 18(15):1627-1635. PubMed ID: 28858531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of cladribine tablets in people with more active multiple sclerosis: a plain language summary.
    Vermersch P; Galazka A; Dangond F; Damian D; Wong SL; Jack D; Harty G
    Neurodegener Dis Manag; 2022 Dec; 12(6):285-293. PubMed ID: 35920065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic.
    Stępień A; Pogoda-Wesołowska A; Tokarz-Kupczyk E; Słowik A; Puz P; Adamczyk-Sowa M; Kurkowska-Jastrzębska I; Kułakowska A; Chorąży M; Piasecka-Stryczyńska K; Jamróz-Wiśniewska A; Bartosik-Psujek H; Rejdak K
    Neurol Neurochir Pol; 2023; 57(4):371-378. PubMed ID: 37490356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Postponing Treatment in the Second Year of Cladribine Administration: Clinical Trial Simulation Analysis of Absolute Lymphocyte Counts and Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis.
    Terranova N; Hicking C; Dangond F; Munafo A
    Clin Pharmacokinet; 2019 Mar; 58(3):325-333. PubMed ID: 29992396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review.
    Rammohan K; Coyle PK; Sylvester E; Galazka A; Dangond F; Grosso M; Leist TP
    Drugs; 2020 Dec; 80(18):1901-1928. PubMed ID: 33247831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.
    Poveda JL; Trillo JL; Rubio-Terrés C; Rubio-Rodríguez D; Polanco A; Torres C
    Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):295-303. PubMed ID: 31220959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets.
    De Stefano N; Giorgio A; Battaglini M; De Leucio A; Hicking C; Dangond F; Giovannoni G; Sormani MP
    Mult Scler; 2018 Feb; 24(2):222-226. PubMed ID: 28140753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study.
    Rejdak K; Stelmasiak Z; Grieb P
    Mult Scler Relat Disord; 2019 Jan; 27():117-120. PubMed ID: 30368223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
    Comi G; Cook S; Giovannoni G; Rieckmann P; Sørensen PS; Vermersch P; Galazka A; Nolting A; Hicking C; Dangond F
    Mult Scler Relat Disord; 2019 Apr; 29():168-174. PubMed ID: 30885375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New hypointense lesions on MRI in relapsing-remitting multiple sclerosis patients.
    Wagner S; Adams H; Sobel DF; Slivka LS; Sipe JC; Romine JS; Koziol JA
    Eur Neurol; 2000; 43(4):194-200. PubMed ID: 10828648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study.
    Gorrod HB; Latimer NR; Damian D; Hettle R; Harty GT; Wong SL
    Value Health; 2019 Jul; 22(7):772-776. PubMed ID: 31277823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cladribine for multiple sclerosis.
    Drug Ther Bull; 2018 Feb; 56(2):21-24. PubMed ID: 29449328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Promising outcomes from Phase III CLARITY study for the treatment of multiple sclerosis announced.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):198. PubMed ID: 19527090
    [No Abstract]   [Full Text] [Related]  

  • 36. Cladribine tablets: in relapsing-remitting multiple sclerosis.
    Muir VJ; Plosker GL
    CNS Drugs; 2011 Mar; 25(3):239-49. PubMed ID: 21323395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study.
    Brownlee W; Amin A; Ashton L; Herbert A
    Mult Scler Relat Disord; 2023 Nov; 79():104951. PubMed ID: 37639781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies.
    Mao Z; Álvarez-González C; Allen-Philbey K; De Trane S; Yildiz O; Campion T; Adams A; Turner BP; Marta M; Gnanapavan S; Espasandin M; Mathews J; Giovannoni G; Baker D; Schmierer K
    Mult Scler Relat Disord; 2019 Jan; 27():247-253. PubMed ID: 30419510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis:
    Vermersch P; Galazka A; Dangond F; Damian D; Wong SL; Jack D; Harty G
    Curr Med Res Opin; 2021 Mar; 37(3):459-464. PubMed ID: 33331183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Oral cladribine for relapsing-remitting multiple sclerosis: another purine analogue or a genuine therapeutic innovation?].
    Schmidt S
    Nervenarzt; 2010 Oct; 81(10):1231-41. PubMed ID: 20567960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.